Callan Family Office LLC Purchases 47,264 Shares of BioMarin Pharmaceutical Inc. $BMRN

Callan Family Office LLC grew its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 239.0% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 67,038 shares of the biotechnology company's stock after buying an additional 47,264 shares during the period. Callan Family Office LLC's holdings in BioMarin Pharmaceutical were worth $3,685,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. V Square Quantitative Management LLC acquired a new stake in BioMarin Pharmaceutical in the 2nd quarter worth approximately $25,000. Farther Finance Advisors LLC boosted its stake in BioMarin Pharmaceutical by 95.9% in the 1st quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 211 shares in the last quarter. Rise Advisors LLC acquired a new stake in BioMarin Pharmaceutical in the 1st quarter worth approximately $30,000. Brooklyn Investment Group boosted its stake in BioMarin Pharmaceutical by 2,250.0% in the 1st quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company's stock worth $40,000 after purchasing an additional 540 shares in the last quarter. Finally, Banque Transatlantique SA acquired a new stake in BioMarin Pharmaceutical in the 1st quarter worth approximately $71,000. 98.71% of the stock is currently owned by institutional investors.

BioMarin Pharmaceutical Stock Performance

Shares of NASDAQ BMRN opened at $52.32 on Friday. The company has a current ratio of 5.56, a quick ratio of 3.60 and a debt-to-equity ratio of 0.10. BioMarin Pharmaceutical Inc. has a 12 month low of $51.78 and a 12 month high of $73.51. The company has a 50 day simple moving average of $56.37 and a two-hundred day simple moving average of $58.19. The stock has a market cap of $10.05 billion, a price-to-earnings ratio of 15.53, a PEG ratio of 0.68 and a beta of 0.33.

Analysts Set New Price Targets

BMRN has been the subject of a number of recent analyst reports. Wall Street Zen cut shares of BioMarin Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday. HC Wainwright initiated coverage on shares of BioMarin Pharmaceutical in a research note on Monday, September 8th. They issued a "neutral" rating and a $60.00 target price for the company. JPMorgan Chase & Co. lifted their target price on shares of BioMarin Pharmaceutical from $116.00 to $119.00 and gave the stock an "overweight" rating in a research note on Thursday. Guggenheim lifted their price objective on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the company a "buy" rating in a research note on Wednesday, August 6th. Finally, Raymond James Financial assumed coverage on shares of BioMarin Pharmaceutical in a research note on Wednesday, September 3rd. They set an "outperform" rating and a $85.00 price objective for the company. Thirteen research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $93.26.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.